Gold prices edge lower; heading for weekly losses ahead of U.S.-Russia talks
Patrick R. O’Neil, Executive Vice President, Chief Legal Officer & General Counsel of Ionis Pharmaceuticals Inc. (NASDAQ:IONS), recently sold 6,165 shares of the company’s common stock. The shares were sold at an average price of $31.6203, amounting to a total transaction value of approximately $194,939. Following this transaction, O’Neil holds 57,452 shares in the company. The sale was conducted as part of a Rule 10b5-1 Trading Plan, which O’Neil adopted on February 21, 2024. According to InvestingPro, Ionis maintains strong liquidity with a current ratio of 8.91, and investors should note the company’s upcoming earnings report on February 19. Get comprehensive insider trading analysis and more with InvestingPro’s detailed research reports, available for 1,400+ US stocks.
In other recent news, Ionis Pharmaceuticals has seen significant developments in its drug portfolio and financial performance. The company’s spinal muscular atrophy (SMA) drug, nusinersen, is under review by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for a higher dose regimen, potentially advancing SMA care. The drug is currently commercialized under the brand name SPINRAZA in over 71 countries.
Simultaneously, Ionis received FDA approval for olezarsen (TRYNGOLZA) for adults with familial chylomicronemia syndrome (FCS). This marks Ionis Pharmaceuticals’ first solo commercial drug launch, with an annual cost of $595,000. Piper Sandler projects $37 million in U.S. FCS revenue for the fiscal year 2025.
Furthermore, Ionis reported its third-quarter financial results for 2024, emphasizing non-GAAP financial results to better reflect the company’s business operations. These recent developments reflect Ionis Pharmaceuticals’ ongoing efforts in advancing its drug portfolio and financial performance. The company’s progress is closely monitored by stakeholders in the healthcare community and its investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.